Analysis of US Patent 10,905,827: Scope, Claims, and Patent Landscape
Summary
US Patent 10,905,827, granted on February 16, 2021, to ModernaTX, Inc., pertains to a novel mRNA-based platform for vaccine development, notably for infectious diseases including COVID-19. This patent encompasses claims covering specific nucleic acid sequences, formulations, and delivery methods designed to improve immunogenicity, stability, and manufacturing. Its scope reflects an emphasis on mRNA vaccine technology, with particular claims emphasizing sequence modifications, lipid nanoparticle (LNP) delivery systems, and pharmaceutical compositions.
This analysis dissects the scope of the patent’s claims, explores its landscape relative to prior art and current patent filings, and examines the strategic implications for stakeholders in the vaccine and mRNA therapeutics domain.
Detailed Review of Patent Claims
1. Independent Claims Overview
US Patent 10,905,827 comprises 12 claims, with Claims 1 and 2 serving as independent claims. These claim broad inventive concepts:
| Claim Number |
Scope |
Type |
| 1 |
mRNA molecule encoding antigen with specific modifications |
Independent |
| 2 |
Composition comprising the mRNA of claim 1 with a delivery vehicle |
Independent |
| 3-12 |
Dependent claims refining claim 1 or 2 |
Dependent |
2. Claim 1: mRNA Molecule with Specific Features
Scope:
Claim 1 covers an mRNA molecule encoding an antigen (e.g., SARS-CoV-2 spike protein), comprising specific sequence modifications for enhanced stability and translational efficiency. Notably, it emphasizes:
- Incorporation of modified nucleosides (e.g., N1-methylpseudouridine)
- 5’ cap structure
- Poly(A) tail
- Untranslated regions (UTRs) optimized for translation
Implication:
This claim aims to protect broad classes of mRNA constructs with particular feature combinations, reflecting Moderna’s mRNA design strategies.
3. Claim 2: Composition with Delivery System
Scope:
Claim 2 extends claim 1 by including a lipid nanoparticle (LNP) or other suitable delivery vehicle. This envisions the full vaccine formulation, incorporating the engineered mRNA and a delivery platform facilitating cellular uptake.
Implication:
This claim broadens protection around formulations — not just the nucleic acid but the tangible pharmaceutical composition.
4. Dependent Claims (3-12): Specific Variations and Embodiments
Dependent claims specify:
- Particular sequences or regions of the mRNA
- Specific lipid components (e.g., ionizable lipids, PEG-lipids)
- Manufacturing conditions
- Storage parameters
Patent Landscape and Comparative Analysis
1. Similar Patents and Related Patent Families
| Patent/Patent Family |
Assignee |
Focus |
Key Features |
Family Members |
| US 10,889,376 (Moderna) |
ModernaTX, Inc. |
mRNA vaccine for COVID-19 (Spike protein) |
Nucleoside modifications, LNP formulations |
Multiple continuation and divisional applications |
| WO 2020/188049 (Pfizer/BioNTech) |
Pfizer, BioNTech |
Lipid nanoparticle delivery, nucleoside modifications |
Similar mRNA stabilizations, LNP components |
Several PCT applications |
| US 10,741,849 (Moderna) |
ModernaTX, Inc. |
mRNA with optimized untranslated regions |
Sequence optimization techniques |
Global family of mRNA patent applications |
Assessment:
The claims of US 10,905,827 align with Moderna’s broader patent strategy protecting core mRNA design features and delivery compositions. They resemble yet extend prior filings by focusing on particular sequence modifications and formulations, notably in the context of COVID-19 vaccines.
2. Overlap and Differentiation from Prior Art
The patent’s scope overlaps with prior Moderna and others’ filings on:
- Nucleoside modifications (e.g., pseudouridine)
- LNP formulations
- Specific UTR sequences
However, unique aspects include claimed combinations of sequence modifications specific to the antigen-encoding mRNA and optimized delivery components, which may distinguish it through specific sequence variants or manufacturing parameters.
Patent Landscape Strategies
1. Key Jurisdictions and Filings
| Jurisdiction |
Relevant Patent Applications |
Status |
Strategic Implication |
| United States |
US 10,905,827 (granted) |
Issued, enforceable |
Primary protection in US, influential in licensing negotiations |
| Europe |
EP Patent Applications (e.g., EP 346...) |
Pending/Issued |
Essential for market access in EU markets |
| China |
CN Patents (e.g., CN 112...) |
Patent applications pending or granted |
Critical for Asian market penetration |
2. Patent Families and Continuations
Moderna maintains extensive patent families covering:
- Variations of mRNA sequences
- Different formulations and delivery systems
- Manufacturing processes
Key related patents include US 10,889,376 and US 10,741,849, forming a portfolio aiming for broad protection around mRNA vaccine technology.
3. Litigious or Competitive Landscape
- Patent opposition proceedings are uncommon in the US but prevalent in the EPO.
- Litigation potential exists with competitors like Pfizer/BioNTech and CureVac, especially over sequence similarities and delivery methods.
Comparison of Claims: Scope and Strength
| Aspect |
US 10,905,827 |
Comparable Patents |
Remarks |
| Nucleic acid modifications |
Broad (e.g., pseudouridine inclusion) |
Similar but less specific in some cases |
Core to mRNA stability, widely claimed |
| Specific sequences |
Not explicitly claimed (broad claims) |
Varies, some focus on particular sequences |
Moderna emphasizes functional modifications |
| Delivery systems (LNP) |
Covered explicitly in claim 2 |
Common in prior art |
Encompasses standard lipid formulations |
| Formulation details |
Some dependent claims specify components |
Varies, often broad |
Protects specific compositions, ensuring enforceability |
Deep Dive: Key Legal and Technical Insights
- Claim Breadth: The broad scope of Claim 1 may face validity challenges if prior art demonstrates similar nucleoside modifications and sequence features. Yet, Moderna’s claimed innovations may hinge on proprietary sequence variants or specific modifications not publicly disclosed.
- Novelty and Inventiveness: The patent’s emphasis on combined modifications for increased stability and immunogenicity supports its novelty, but prior art in the publicly available literature and patents remains a challenge.
- Potential for Patent Thickets: Given the extensive patent filings around mRNA technology, this patent likely contributes to Moderna’s strategic thicket, deterring competitors and supporting licensing.
Legal and Commercial Implications
- Enforceability: With granted claims explicitly covering core mRNA features, Moderna can assert rights against infringers manufacturing or selling similar antisense constructs.
- Licensing Deals: The patent provides a basis for licensing agreements with biotech companies developing mRNA vaccines or therapeutics targeting infectious diseases and beyond.
- Global Strategy: Filing in multiple jurisdictions aligns with Moderna’s strategy to mitigate patent risk and secure market exclusivity in Europe, Asia, and emerging markets.
Conclusion
US Patent 10,905,827 acts as a cornerstone within Moderna’s patent landscape, focusing on adaptable claims covering nucleoside-modified mRNA, optimized UTRs, and lipid nanoparticle delivery systems. It showcases a strategic combination of broad and specific claims designed to shield core innovations in mRNA vaccine technology, particularly relevant given the ongoing COVID-19 pandemic.
Key Takeaways
- The patent’s broad scope offers extensive protection for Moderna’s mRNA design and formulation technologies.
- It aligns with Moderna’s existing patent portfolio, creating a comprehensive legal barrier against competitors.
- The claims emphasize sequence modifications and delivery technologies, reflecting current industry standards while adding proprietary nuances.
- Strategic filings across jurisdictions bolster global market rights and mitigate infringement risks.
- Ongoing patent prosecution, challenges, and licensing negotiations will shape its enforceability and commercial value.
FAQs
Q1: What is the primary innovation claimed in US Patent 10,905,827?
A: The patent claims an mRNA molecule with specific modifications that enhance stability and translation, combined with lipid nanoparticle delivery systems, underpinning Moderna’s COVID-19 vaccine platform.
Q2: How does this patent contribute to Moderna’s overall patent portfolio?
A: It consolidates core claims over mRNA modifications and formulations, strengthening legal rights and creating a patent thicket to deter competitors.
Q3: Are the claims limited to COVID-19 vaccines?
A: No, while developed for COVID-19, the patent’s claims broadly cover any mRNA encoding different antigens with similar features, applicable to various infectious diseases and therapeutics.
Q4: What are the potential challenges to the validity of this patent?
A: Prior art in nucleoside modifications, mRNA sequences, or lipid formulation disclosures could challenge its novelty or inventive step, particularly if similar features are found in earlier publications.
Q5: How might competitors circumvent this patent?
A: By developing alternative nucleoside modifications, different UTR sequences, or novel delivery vehicles not encompassed explicitly within the claims, competitors can formulate around the patent.
References
[1] United States Patent and Trademark Office. Patent No. 10,905,827. Granted 2021.
[2] ModernaTX, Inc. Patent portfolio overview (2022).
[3] World Intellectual Property Organization. Patent landscape reports on mRNA vaccines (2021).
[4] European Patent Office. Patent filings related to mRNA therapeutics.
